Phase III study of KRP-114V

A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of The Beta-3 Agonist KRP-114V in Japanese Subjects With Symptoms of Overactive Bladder

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222884

Enrollment

1090

Registered

2015-06-17

Start date

2015-06-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder(OAB)

Interventions

investigational material(s) Generic name etc : KRP-114V INN of investigational material : Therapeutic category code : 251 Agents affecting urinary organs Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient showing clear OAB symptoms

Exclusion criteria

Exclusion criteria: Patients complicated with urinary tract infection, urinary stones, and/or interstitial cystitis Patients with a previous history of recurrent urinary tract infection Patients confirmed to have a post-void residual volume of more than 100 mL

Design outcomes

Primary

Measure	Time frame
Efficacy ( The average number of micturitions per 1 day) Bladder diary	—

Secondary

Measure	Time frame
Efficacy (The average number of urgency per 1 day, etc.), Safety Bladder diary, Adverse event and adverse drug reaction	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026